<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04800302</url>
  </required_header>
  <id_info>
    <org_study_id>USGCQLBIIIPCNL</org_study_id>
    <nct_id>NCT04800302</nct_id>
  </id_info>
  <brief_title>U/S-guided Continuous Quadratus Lumborum Block III in Percutaneous Nephrolithotomy</brief_title>
  <official_title>Ultrasound-guided Continuous Quadratus Lumborum Block III for Postoperative Analgesia in Percutaneous Nephrolithotomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nazmy Edward Seif</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Percutaneous nephrolithotomy (PCNL) is considered to be the first choice and a more&#xD;
      conservative procedure than open stone surgery. Not only postoperative pain related to&#xD;
      dilatation of the renal capsule and parenchymal tract, but also patient's discomfort &amp;&#xD;
      nephrostomy tube-related stress are reported to delay recovery time and increase the&#xD;
      complication rates. This study is designed to provide postoperative analgesia by using&#xD;
      ultrasound-guided continuous Quadratus Lumborum Block (QLB) III in patients undergoing PCNL&#xD;
      and to assess pain scores &amp; side effects with less opioids consumption.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morphine consumption.</measure>
    <time_frame>24 hours</time_frame>
    <description>Total dose of Morphine (measured in mg) given intra-venously to the patient post-operatively.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Analgesia</condition>
  <condition>Surgery</condition>
  <condition>Renal Stone</condition>
  <arm_group>
    <arm_group_label>Continuous QLB group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>U/S-guided continous QLB III</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose QLB group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>U/S-guided single dose QLB III</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV Morphine</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Continous Quadratum Lumborum Block III</intervention_name>
    <description>Continuous infusion of Bupivacaine 0.125 % at a rate of 0.1 ml/kg/hr (not exceeding 12 ml/hour), infused through a catheter inserted in the plane between quadratus lumborum &amp; psoas major muscles with ultrasound guidance.</description>
    <arm_group_label>Continuous QLB group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Single dose Quadratum Lumborum Block III</intervention_name>
    <description>Single injection of a mixture solution of 20 ml Bupivacaine 0.5% + 10 ml Lidocaine 2%, injected through a needle inserted at the posterior aspect of the quadratus lumborum muscle between it and erector spinae muscle with ultrasound guidance.</description>
    <arm_group_label>Continuous QLB group</arm_group_label>
    <arm_group_label>Single dose QLB group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intra-venous Morphine</intervention_name>
    <description>Intra-venous Morphine [0.1 mg/kg] as rescue analgesic shots when the Visual Analogue Score (VAS) for pain exceeds 4.</description>
    <arm_group_label>Continuous QLB group</arm_group_label>
    <arm_group_label>Morphine group</arm_group_label>
    <arm_group_label>Single dose QLB group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA I-II.&#xD;
&#xD;
          -  Scheduled for percutaneous nephrolithotomy (PCNL).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusal.&#xD;
&#xD;
          -  Coagulation disorders.&#xD;
&#xD;
          -  Skin lesions or infection at site of needle insertion.&#xD;
&#xD;
          -  Known allergy to local anesthetics or opioids.&#xD;
&#xD;
          -  Patients suffering from neurological or mental disease.&#xD;
&#xD;
          -  Procedure turned into open stone surgery.&#xD;
&#xD;
          -  Failure of identification by U/S.&#xD;
&#xD;
          -  Urinary tract malignancies.&#xD;
&#xD;
          -  Opioid consumption 48 hours before the operation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherif A Embaby, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kasr Al-Ainy Hospital, Faculty of Medicine, Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherif A Embaby, MSc</last_name>
    <phone>01003852294</phone>
    <phone_ext>+2</phone_ext>
    <email>sherif_embaby@live.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yahya M Hammad, MD</last_name>
    <phone>01114048081</phone>
    <phone_ext>+2</phone_ext>
    <email>yahya196cm@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cairo University Hospitals</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherif A Embaby, MSc</last_name>
      <phone>01003852294</phone>
      <phone_ext>+2</phone_ext>
      <email>sherif_embaby@live.com</email>
    </contact>
    <contact_backup>
      <last_name>Yahya M Hammad, MD</last_name>
      <phone>01114048081</phone>
      <phone_ext>+2</phone_ext>
      <email>yahya196cm@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 12, 2021</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Nazmy Edward Seif</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Quadratus Lumborum Block III</keyword>
  <keyword>Ultrasound-guided</keyword>
  <keyword>Percutaneous nephrolithotomy</keyword>
  <keyword>Analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

